A high-throughput screen to identify inhibitors of amyloid β-protein precursor processing

Journal of Biomolecular Screening

Volumn 10, Issue 1, 2005, Pages 1-12

  Bakshi, Pancham ^a,b   Liao, Yung Feng ^a   Gao, Jun ^a   Ni, Jake ^b   Stein, Ross ^b   Yeh, Li An ^b   Wolfe, Michael S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

secretase; Alzheimer's disease; Amyloid; High throughput screening; Luciferase

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GALACTOSE; GAMMA SECRETASE; LUCIFERASE; PROTEIN INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENDOPEPTIDASES; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSFECTION;

EID: 17044427901     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104270068     Document Type: Article

References (31)

1. Campion D, Dumanchin C, Mannequin D, et al: Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664-670.
2. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-159.
3. Jarrett JT, Berger EP, Lansbury PT Jr: The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 1993;695:144-148.
4. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
5. Wolfe MS: Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002;1:859-866.
6. Buxbaum JD, Liu KN, Luo Y, et al: Evidence that tumor necrosis factor α converting enzyme is involved in regulated a-secretase cleavage of the Alzheimer's amyloid protein precursor. J Biol Chem 1998;273:27765-27767.
7. Vassar R: BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004;23:105-114.
8. De Strooper B: Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 2003;38:9-12.
9. Shearman MS, Beher D, Clarke EE, et al: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 2000;39:8698-8704.
10. Moore CL, Leatherwood DD, Diehl TS, Selkoe DJ, Wolfe MS: Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's γ-secretase: implications for inhibitor design. J Med Chem 2000;43:3434-3442.
11. Li YM, Xu M, Lai MT, et al: Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000;405:689-694.
12. Esler WP, Kimberly WT, Ostaszewski BL, et al: Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol 2000;2:428-434.
13. Wolfe MS, Xia W, Moore CL, et al: Peptidomimetic probes and molecular modeling suggest Alzheimer's γ-secretases are intramembrane-cleaving aspartyl proteases. Biochemistry 1999;38:4720-4727.
14. Fiore F, Zambrano N, Minopoli G, Donini V, Duilio A, Russo T: The regions of the Fe65 protein homologous to the phosphotyrosine interaction/ phosphotyrosine binding domain of She bind the intracellular domain of the Alzheimer's amyloid precursor protein. J Biol Chem 1995;270:30853-30856.
15. Zambrano N, Buxbaum JD, Minopoli G, et al: Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins. J Biol Chem 1997;272:6399-6405.
16. Ermekova KS, Zambrano N, Linn H, et al: The WW domain of neural protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila enabled. J Biol Chem 1997;272:32869-32877.
17. Cao X, Sudhof TC: A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001;293:115-120.
18. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS: A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 1998;4:730-734.
19. Amour A, Knight CG, Webster A, et al: The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000;473:275-279.
20. Hom RK, Gailunas AF, Mamo S, et al: Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 2004;47:158-164.
21. Esler WP, Kimberly WT, Ostaszewski BL, et al: Activity-dependent isolation of the presenilin/γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci USA 2002;99:2720-2725.
22. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E: Tetracycline represser, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 1998;9:1939-1950.
23. Hillen W, Gatz C, Altschmied L, Schollmeier K, Meier I: Control of expression of the Tn10-encoded tetracycline resistance genes: equilibrium and kinetics investigation of the regulatory reactions. J Mol Biol 1983;169:707-721.
24. Seiffert D, Bradley JD, Rominger CM, et al: Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 2000;275:34086-34091.
25. Zhang JH, Chung TD, Oldenberg KR: A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999;4:67-73.
26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
27. Gianni D, Zambrano N, Bimonte M, et al: Platelet-derived growth factor induces the β-, γ-secretase-mediated cleavage of Alzheimers amyloid precursor protein through a Src-Rac-dependent pathway. J Biol Chem 2003;278:9290-9297.
28. Buxbaum JD, Koo EH. Greengard P: Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci USA 1993;90:9195-9198.
29. Hung AY, Haass C, Nitsch RM, et al: Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993;268:22959-22962.
30. Felsenstein KM, Ingalls KM, Hunihan LW, Roberts SB: Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate. Neurosci Lett 1994;174:173-176.
31. Jacobsen JS, Spruyt MA, Brown AM, et al: The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. J Biol Chem 1994;269:8376-8382.